Abstract
Previous studies suggested that abnormal miRNA expression was a significant characteristic of malignant tumors. We aimed to explore the role of miR-106a as the potential diagnostic and prognostic biomarker in gastric cancer (GC). Firstly, the expression level of miR-106a was detected by qPCR in 28 pairs of GC cancer tissues and adjacent tissues, 48 pairs of plasma samples before and after operation from GC patients, and 22 plasma samples from healthy controls. It had revealed that the level of miR-106a in tumor tissues (2.700±2.565) was significantly higher compared to adjacent tissues (1.321±0.904) (p<0.05). Besides, the expression level of miR-106a in plasma of GC (9.479±5.595) was significantly up-regulated compared with healthy controls (2.594±2.329) (p<0.05), while a remarkable decline of miR- 106a expression was observed in plasma of GC patients after gastrectomy. Further statistic data showed high miR-106a expression was closely related to the degree of lymphatic metastasis and TNM staging of GC. We also applied ROC curve in order to evaluate miR-106a as a diagnostic marker for GC patients. As a result, the sensitivity and specificity were 60.4%, 68.2% in tissue samples and 72.9%, 63.6% in plasma samples, respectively. At last, we explored the methylation status of miR-106a promoter in 28 paired GC tissues through methylation-specific PCR (MSP), the result showed that the methylation rate was 53.6% in cancer tissues and 85.7% in adjacent tissues. Moreover, the result indicated that promoter hypomethylation of miR- 106a is related to its high expression. Our research indicated that miR-106a might serve as a potential prognostic indicator in progressive GC and up-regulated circulating miR-106a by promoter hypomethylation, might be proposed as a candidate diagnostic and prognostic indicator for GC.
Keywords: Gastric cancer, miR-106a, methylation regulation, oncogenic miRNA, TNM stage, lymph node metastasis.
Anti-Cancer Agents in Medicinal Chemistry
Title:Up-regulated Circulating miR-106a by DNA Methylation Promised a Potential Diagnostic and Prognostic Marker for Gastric Cancer
Volume: 16 Issue: 9
Author(s): Renshun Yuan, Gang Wang, Zhihua Xu, Hong Zhao, Huabin Chen, Ye Han, Bin Wang, Jin Zhou, Hao Hu, Zhaoji Guo, Hugang Shen and Xiaofeng Xue
Affiliation:
Keywords: Gastric cancer, miR-106a, methylation regulation, oncogenic miRNA, TNM stage, lymph node metastasis.
Abstract: Previous studies suggested that abnormal miRNA expression was a significant characteristic of malignant tumors. We aimed to explore the role of miR-106a as the potential diagnostic and prognostic biomarker in gastric cancer (GC). Firstly, the expression level of miR-106a was detected by qPCR in 28 pairs of GC cancer tissues and adjacent tissues, 48 pairs of plasma samples before and after operation from GC patients, and 22 plasma samples from healthy controls. It had revealed that the level of miR-106a in tumor tissues (2.700±2.565) was significantly higher compared to adjacent tissues (1.321±0.904) (p<0.05). Besides, the expression level of miR-106a in plasma of GC (9.479±5.595) was significantly up-regulated compared with healthy controls (2.594±2.329) (p<0.05), while a remarkable decline of miR- 106a expression was observed in plasma of GC patients after gastrectomy. Further statistic data showed high miR-106a expression was closely related to the degree of lymphatic metastasis and TNM staging of GC. We also applied ROC curve in order to evaluate miR-106a as a diagnostic marker for GC patients. As a result, the sensitivity and specificity were 60.4%, 68.2% in tissue samples and 72.9%, 63.6% in plasma samples, respectively. At last, we explored the methylation status of miR-106a promoter in 28 paired GC tissues through methylation-specific PCR (MSP), the result showed that the methylation rate was 53.6% in cancer tissues and 85.7% in adjacent tissues. Moreover, the result indicated that promoter hypomethylation of miR- 106a is related to its high expression. Our research indicated that miR-106a might serve as a potential prognostic indicator in progressive GC and up-regulated circulating miR-106a by promoter hypomethylation, might be proposed as a candidate diagnostic and prognostic indicator for GC.
Export Options
About this article
Cite this article as:
Yuan Renshun, Wang Gang, Xu Zhihua, Zhao Hong, Chen Huabin, Han Ye, Wang Bin, Zhou Jin, Hu Hao, Guo Zhaoji, Shen Hugang and Xue Xiaofeng, Up-regulated Circulating miR-106a by DNA Methylation Promised a Potential Diagnostic and Prognostic Marker for Gastric Cancer, Anti-Cancer Agents in Medicinal Chemistry 2016; 16 (9) . https://dx.doi.org/10.2174/1871520615666150716110657
DOI https://dx.doi.org/10.2174/1871520615666150716110657 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Advances in Nanomedicines and Targeted Therapies for Colorectal Cancer
Colorectal cancer remains a significant global health challenge, with high incidence and mortality rates despite advancements in treatment strategies. Conventional therapies often face limitations such as systemic toxicity, drug resistance, and suboptimal targeting. The advent of nanomedicines and innovative drug delivery systems offers new hope for overcoming these challenges and ...read more
Discovery of Lead compounds targeting transcriptional regulation
Transcriptional regulation plays key physiological functions in body growth and development. Transcriptional dysregulation is one of the important biomarkers of tumor genesis and progression, which is involved in regulating tumor cell processes such as cell proliferation, differentiation, and apoptosis. Additionally, it plays a pivotal role in angiogenesis and promotes tumor ...read more
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes that aid in stabilizing chromosomal makeup. The resynthesis of telomeres is supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no telomerase activity in human somatic cells, but the stem cells and germ cells undergo ...read more
Innovative targets in medicinal chemistry
Medicinal chemistry continuously evolves in response to emerging healthcare needs and advancements in scientific understanding. This special issue explores the current landscape of innovative targets in medicinal chemistry, highlighting the quest for novel therapeutic avenues. From traditional drug targets such as enzymes and receptors to emerging targets like protein-protein interactions ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pharmacophore and Binding Analysis of Known and Novel B-RAF Kinase Inhibitors
Current Medicinal Chemistry Targeting Sugar Uptake and Metabolism for Cancer Identification and Therapy: An Overview
Current Topics in Medicinal Chemistry Resveratrol and Clinical Trials: The Crossroad from In Vitro Studies to Human Evidence
Current Pharmaceutical Design Biotechnological Applications of Trametes versicolor and their Enzymes
Current Biotechnology Structural Biology of Bacterial Secretion Systems in Gram-Negative Pathogens- Potential for New Drug Targets
Infectious Disorders - Drug Targets Potential Role of Natural Compounds Against Skin Aging
Current Medicinal Chemistry Recent Advances of Metal Binding Protein Lactoferrin as an Anti- Microbial Agent
Current Bioactive Compounds Decreased Parathyroid Hormone Levels Despite Persistent Hypocalcemia in Patients with Kidney Failure Recovering from Septic Shock
Endocrine, Metabolic & Immune Disorders - Drug Targets Contemporary Progress in the Synthetic Strategies of Imidazole and its Biological Activities
Current Organic Synthesis Nicotine, Lung and Cancer
Anti-Cancer Agents in Medicinal Chemistry Review of Phytosomes and Ethosomes: Groundbreaking Approaches for Delivering the Phytochemical Components of Plants
Current Drug Delivery The Purinome, a Complex Mix of Drug and Toxicity Targets
Current Topics in Medicinal Chemistry Metabolism and the Paradoxical Effects of Arsenic: Carcinogenesis and Anticancer
Current Medicinal Chemistry PPARδ Signaling Regulates Colorectal Cancer
Current Pharmaceutical Design Combined Treatment with Octreotide, Galanin and Serotonin in Gastrointestinal Malignancies
Letters in Drug Design & Discovery A Comparative Analysis of Methods for Titering Reovirus
Pharmaceutical Nanotechnology Calorie Restriction and Dietary Restriction Mimetics: A Strategy for Improving Healthy Aging and Longevity
Current Pharmaceutical Design The Involvement of Metallothioneins in Mitochondrial Function and Disease
Current Protein & Peptide Science Targeting Drugs Against Fibroblast Growth Factor(s)-Induced Cell Signaling
Current Drug Targets Hormones and the Autonomic Nervous System are Involved in Suprachiasmatic Nucleus Modulation of Glucose Homeostasis
Current Diabetes Reviews